Skip to main content

Table 2 Table showing localisation of recurrence, pathologic and treatment characteristics and outcome of patients with local and metastatic recurrence

From: Outcome of recurrent and metastatic small cell carcinoma of the bladder

Localisation of recurrence Histology (Mixed or pure SmCC) Treatment Response Survival (months) Death
Rectum mixed Surgery + CT (3EP) + RT Progressive 7.1 yes
Neo-bladder Mixed CT (6MVAC) PR < 50% 10 yes
RP Pure CT (4EP) Stable 5.5 yes
RP Mixed RT (Y 45 Gy) + chemotherapy (4G) Stable 7.7 yes
RP Mixed CT (4GC) + RT (Y 45 Gy) CR 28.8 yes
CNS Pure CT (1 EP + 1 MTX intrathecal) - 0.4 yes
CNS Pure RT (30 Gy) Progressive 3.7 yes
Liver and RP Mixed CT (1GC) Progressive 0.7 yes
Liver and RP Mixed CT (4G) Progressive 3.1 yes
Liver and Bone Pure CT (6EP) PR > 50% 20.3 no
Lung and RP Mixed CT (6EP) PR > 50% 14.7 no
Lung Mixed CT (6EP in first line and 6GC in second line) PR > 50% (in first line) 26.3 yes
  1. SmCC = small cell carcinoma; CNS = central nervous system; RP = retroperitoneal; EP = etoposide and cisplatin; G = gemcitabine; GC = gemcitabine plus cisplatin; MVAC = methotrexate, vinblastine, doxorubicin and cisplatin; MTX = methotrexate; CT = chemotherapy; RT = radiotherapy; Y = Y field radiotherapy; PR = partial response; CR = complete response, NA = not applicable